Voyager Therapeutics (NASDAQ: VYGR) reported Q1 EPS of ($0.53), $0.08 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $6.47 million versus the consensus estimate of $12.95 million.

For earnings history and earnings-related data on Voyager Therapeutics (VYGR) click here.